YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and used the moment to narrow its focus: the company is now prioritizing BBO-8520 paired with a checkpoint…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Karyopharm Therapeutics and Amgen, as well as update…
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is one of the most promising stocks on our list. TheFly reported on June 22 that Oppe…
On May 15, 2026, Cormorant Asset Management disclosed a buy of 313,645 shares of Alumis(NASDAQ:ALMS), with the estimated transaction value at $7.84 million based on quarterly average pricing. What happened According to a May 15, 2026 SEC f…
On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics(NASDAQ:DNTH), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Secu…
Cormorant Asset Management disclosed a new position in Erasca(NASDAQ:ERAS) in its May 15, 2026, SEC filing, purchasing 5,800,000 shares in a trade estimated at $68.55 million based on quarterly average pricing. What happened According to i…
Key Points Cormorant Asset Management bought 5,800,000 Erasca shares in the first quarter, an estimated $68.55 million trade based on quarterly average pricing. The quarter-end position value rose by $93.84 million, reflecting both share p…
Omega Fund Management disclosed a buy of 187,500 shares of Bicara Therapeutics(NASDAQ:BCAX) in a May 15, 2026, SEC filing, with the estimated transaction value at $3.23 million based on quarterly average pricing. What happened According to…
On May 15, 2026, Omega Fund Management disclosed in an SEC filing that it sold 411,968 shares of Alumis(NASDAQ:ALMS), with the estimated transaction value at $10.3 million based on quarterly average pricing. What happened According to its…
Omega Fund Management cut its stake in Kestra Medical Technologies (NASDAQ:KMTS), selling 351,442 shares in the first quarter for an estimated $8.28 million based on quarterly average pricing, according to a May 15, 2026, SEC filing. What…
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS in…
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducem…
Quick Read: Technologuy stocks helped lead the stock market higher on Friday, alongside a very positive April jobs report. First-quarter earnings have been outstanding, with 84% of reporting companies beating estimates. As we head into sum…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news from Eli Lilly and the Food and Drug Administration, as well a…
(RTTNews) - BridgeBio Oncology Therapeutics Inc. (BBOT), a clinical-stage biopharmaceutical company, on Tuesday presented preclinical data evaluating BBO-10203 in blocking interactions between RAS an PI3Ka in tumors at the 2026 annual meet…
TheRas, Inc. (d/b/a BBOT) Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and sc…
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203 displays strong in vivo co…
(RTTNews) - BridgeBio Oncology Therapeutics, Inc. (BBOT) said the U.S. Food and Drug Administration has granted Fast Track designation to BBO-11818 for the treatment of adults with advanced KRAS-mutant pancreatic ductal adenocarcinoma. The…
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half of 2026 SOUTH SAN F…
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded induc…
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple present…
Cormorant Asset Management disclosed a buy of 2,361,260 shares of MoonLake Immunotherapeutics(NASDAQ:MLTX) in its February 17, 2026 SEC filing, an estimated $27.86 million trade based on quarterly average pricing. What happened According t…
On February 17, 2026, Cormorant Asset Management disclosed in a regulatory filing that it sold its entire stake in Arcellx(NASDAQ:ACLX), an estimated $63.63 million transaction based on last-disclosed position values. What happened Accordi…
Cormorant Asset Management initiated a new position in Olema Pharmaceuticals(NASDAQ:OLMA), buying 2,750,000 shares worth $68.75 million in the fourth quarter, according to a February 17, 2026, SEC filing. What happened Cormorant Asset Mana…
Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside C…
Key Points Cormorant Asset Management sold 50,000 shares of PRAX in the fourth quarter; the estimated trade size was $9.31 million based on quarterly average pricing. Meanwhile, the quarter-end value of the PRAX position increased by $227.…
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG1…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Raymond James initiated BridgeBio Oncology Therapeutics (BBOT [https://seekingalpha.com/symbol/BBOT]) at outperform, noting the company is well capitalized and has several phase 1 da…
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining o…
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F ass…
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F ass…
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an ind…
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of i…
24/7 Wall St. Quick Read Alphabet (GOOG,GOOGL) holds a portfolio of 37 stocks worth $2.5B to $3B through its venture arms GV and CapitalG. Google’s portfolio is heavily tilted toward healthcare and biotech with its largest holding being Pl…
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presen…
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combination activity with BBOT’s KRASG12C ON…